OSE IMMUNO : Invest Securities raises its target
The research firm points out that BI has decided to extend its collaboration initiated since April 2018 with the company, by acquiring a new preclinical asset and expanding the scope of exploration of antibodies already under license.
"OSE Immuno is off to an explosive start to 2024 (+134% since the end of February), supported by major announcements on the business development front", notes the analyst more broadly, also mentioning the licensing agreement signed with Abbvie.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Go to the original article.
Contact us to request a correction